---
title: "Arbutus Biopharma Corporation (ABUS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABUS.US.md"
symbol: "ABUS.US"
name: "Arbutus Biopharma Corporation"
industry: "Biotechnology"
datetime: "2026-05-20T06:50:21.487Z"
locales:
  - [en](https://longbridge.com/en/quote/ABUS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABUS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABUS.US.md)
---

# Arbutus Biopharma Corporation (ABUS.US)

## Company Overview

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.arbutusbio.com](https://www.arbutusbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: A (0.14)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2889.93% |  |
| Net Profit YoY | 309.90% |  |
| P/B Ratio | 3.18 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 827146651.80 |  |
| Revenue | 191445000.00 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 94.73% | A |
| Profit Margin | 83.95% | A |
| Gross Margin | 97.70% | A |
| Revenue YoY | 2889.93% | A |
| Net Profit YoY | 309.90% | A |
| Total Assets YoY | 136.87% | A |
| Net Assets YoY | 228.68% | A |
| Cash Flow Margin | -21.38% | D |
| OCF YoY | 2889.93% | A |
| Turnover | 0.97 | A |
| Gearing Ratio | 6.13% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Arbutus Biopharma Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2889.93%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "309.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.18",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "827146651.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "191445000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "94.73%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "83.95%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "97.70%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2889.93%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "309.90%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "136.87%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "228.68%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-21.38%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "2889.93%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.97",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "6.13%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 5.15 | 18/386 | - | - | - |
| PB | 3.18 | 263/386 | 11.29 | 10.34 | 8.13 |
| PS (TTM) | 4.32 | 96/386 | 93.62 | 59.32 | 54.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.20 |
| Highest Target | 5.50 |
| Lowest Target | 4.91 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABUS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABUS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ABUS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABUS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**